Effect of combination of clopidogrel,daglizin and indolbuprofen on short-term prognosis of T2DM patients with ACS after PCI
AIM To investigate the short-term prognosis of patients with type 2 diabetes mellitus(T2DM)complicated with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI)with clopidogrel,dapagliflozin and indobufen.METHODS A total of 96 patients with T2DM complicated with ACS who underwent PCI in the hospital from June 2020 to December 2022 were randomly divided into control group(48 patients)and study group(48 patients).The control group was treated with aspirin,clopidogrel and dapagliflozin after surgery,and the study group was treated with indobufen,clopidogrel and dapagliflozin after surgery.The blood sugar level,platelet parameters,coagulation function and inflammatory factors were observed before and after treatment for 12 weeks,and the degree of lumen stenosis before and immediately after PCI was compared between 2 groups,and the incidence of adverse events in the six-month follow-up of 2 groups was counted.RESULTS After 12 weeks of treatment,the fasting blood glucose,postprandial blood glucose and glycosylated hemoglobin in 2 groups were lower than those before treatment(P＜0.05),but there was no significant difference between 2 groups(P＞0.05).After 12 weeks of treatment,the platelet count and platelet aggregation rate in both groups were lower than before treatment,and the study group was lower than the control group(P＜0.05).After 12 weeks of treatment,the prothrombin time(PT),thrombin time(TT)and activated partial thromboplastin time(APTT)in both groups were longer than those before treatment,and the fibrinogen(FIB)was lower than that before treatment,and the change range in the study group was higher than that in the control group(P＜0.05).After 12 weeks of treatment,the levels of interleukin-1β(IL-1β),interleukin-6(IL-6)and high-sensitivity C-reactive protein(hs-CRP)in both groups were lower than those before treatment,and the levels in the study group were lower than those in the control group(P＜0.05).At 12th week after operation,the degree of lumen stenosis in the study group was lower than that in the control group(P＜0.05).Within 6 months of follow-up,there was no significant difference in the incidence of adverse events between 2 groups(P＞0.05).CONCLUSION Compared with aspirin,the combined application of clopidogrel,dapagliflozin and indobufen in patients with T2DM complicated with ACS after PCI has better functions in inhibiting platelet activation and aggregation,and anticoagulation,can significantly reduce blood sugar and inflammatory factor levels,has shown good safety profiles,making it suitable for clinical promotion.
type 2 diabetes mellitusacute coronary syndromeclopidogreldapagliflozinindobufen
国家科技期刊平台
NSTL
万方数据
